Sonoporation-Enhanced Chemotherapy Significantly Reduces Primary Tumour Burden in an Orthotopic Pancreatic Cancer Xenograft
- 1k Downloads
Adenocarcinoma of the pancreas remains one of the most lethal human cancers. The high mortality rates associated with this form of cancer are subsequent to late-stage clinical presentation and diagnosis, when surgery is rarely possible and of modest chemotherapeutic impact. Survival rates following diagnosis with advanced pancreatic cancer are very low; typical mortality rates of 50 % are expected within 3 months of diagnosis. However, adjuvant chemotherapy improves the prognosis of patients even after palliative surgery, and successful newer neoadjuvant chemotherapeutical modalities have recently been reported. For patients whose tumours appear unresectable, chemotherapy remains the only option. During the past two decades, the nucleoside analogue gemcitabine has become the first-line chemotherapy for pancreatic adenocarcinoma. In this study, we aim to increase the delivery of gemcitabine to pancreatic tumours by exploring the effect of sonoporation for localised drug delivery of gemcitabine in an orthotopic xenograft mouse model of pancreatic cancer.
An orthotopic xenograft mouse model of luciferase expressing MIA PaCa-2 cells was developed, exhibiting disease development similar to human pancreatic adenocarcinoma. Subsequently, two groups of mice were treated with gemcitabine alone and gemcitabine combined with sonoporation; saline-treated mice were used as a control group. A custom-made focused ultrasound transducer using clinically safe acoustic conditions in combination with SonoVue® ultrasound contrast agent was used to induce sonoporation in the localised region of the primary tumour only. Whole-body disease development was measured using bioluminescence imaging, and primary tumour development was measured using 3D ultrasound.
Following just two treatments combining sonoporation and gemcitabine, primary tumour volumes were significantly lower than control groups. Additional therapy dramatically inhibited primary tumour growth throughout the course of the disease, with median survival increases of up to 10 % demonstrated in comparison to the control groups.
Combined sonoporation and gemcitabine therapy significantly impedes primary tumour development in an orthotopic xenograft model of human pancreatic cancer, suggesting additional clinical benefits for patients treated with gemcitabine in combination with sonoporation.
Key wordsSonoporation Pancreatic cancer Ultrasound Chemotherapy 3D ultrasound Bioluminescence
- 1.American Cancer Society Cancer Facts and Figures (2013) http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf
- 8.Marechal R, Bachet JB, Mackey JR et al (2012) Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 143(664–674):e661–666Google Scholar
- 9.Camp-Sorell D (2010) Chemotherapy toxicities and management. In: Yarbro CH, Wujcik D, Gobel BH (eds) Cancer nursing: principles and practice. Jones & Bartlett, SudburyGoogle Scholar
- 13.Postema MAB (2004) Medical bubbles. Michiel Postema, BergschenhoekGoogle Scholar
- 21.Emmer M, Borsboom J, Van Wamel A, Versluis M, de Jong N (2005) Optical investigation of ultrasound induced encapsulated microbubble oscillations: threshold and hysteresis effects. Proc IEEE Ultrason Symp:981–984Google Scholar
- 30.British Medical Ultrasound Society (2000) Guidelines for the safe use of diagnostic ultrasound equipment. British Medical Ultrasound SocietyGoogle Scholar
- 45.Poortinga AT (2012) Micron-sized antibubbles with tunable stability. Colloids Surf A: Physiochem Eng AspectsGoogle Scholar
- 48.Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB (2007) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67:3853–3861PubMedCrossRefGoogle Scholar